Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02394769 · ClinicalTrials.gov registry record · NA
ASPirin Intervention for the REDuction of Colorectal Cancer Risk
A NA study of Colorectal Cancer, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT02394769: Active NA study of Colorectal Cancer, sponsored by Massachusetts General Hospital.
NCT02394769 is a NA study of Colorectal Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 180 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02394769, a NA study of Colorectal Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer
Primary Outcome
Measured using liquid chromatography/mass spectrometry
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Placebo for Aspirin
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2015-07-06 |
| Est. Completion | 2029-07 |
| Phase | NA |
What the registry record for NCT02394769 still lists
NCT02394769 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.
NCT02394769 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02394769 about?
NCT02394769 is a clinical study titled "ASPirin Intervention for the REDuction of Colorectal Cancer Risk". This research study is investigating the use of aspirin as a potential chemopreventive agent to reduce risk of colorectal cancer
What is the current status of trial NCT02394769?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2015-07-06. Estimated completion is 2029-07.
What conditions does trial NCT02394769 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT02394769?
The interventions under investigation include: Aspirin (DRUG), Placebo for Aspirin (DRUG).
Who is sponsoring clinical trial NCT02394769?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02394769 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02394769's enrollment target sits among peer trials
180 156th of 381 higher than 223 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
-
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI